Original Research
Accepted on 13 Nov 2024
Sorafenib Combined with Tarexib for First-Line Treatment of Unresectable Hepatocellular Carcinoma and Its Predictive Role and Correlation with PD-L1 CTCs
in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers